Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Diabetes

Free Subscription 05.07.2021 2 Acta Ophthalmol 1 Am J Clin Nutr 2 Am J Epidemiol 1 Biochem Biophys Res Commun 1 BMC Pediatr 1 Circ Cardiovasc Imaging 3 Diabet Med 1 Diabetes 15 Diabetes Care 23 Diabetes Obes Metab 3 Diabetologia 1 J Autoimmun 9 J Clin Endocrinol Metab 7 J Diabetes Complications 1 JAMA 1 Kidney Int 2 Lancet 1 Med Care 1 Med J Aust 3 N Engl J Med 1 Ophthalmology 5 Pediatr Diabetes 2 Pediatrics 2 PLoS Med 6 PLoS One 1 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Ophthalmol

1. SCANLON PH, Nevill CR, Stratton IM, Maruti SS, et al
   Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire.
   Acta Ophthalmol. 2021 Jun 28. doi: 10.1111/aos.14927.
   PubMed         Abstract available
   
   
2. FEDOTKINA O, Luk A, Jain R, Prasad RB, et al
   Perinatal famine is associated with excess risk of proliferative retinopathy in patients with type 2 diabetes.
   Acta Ophthalmol. 2021 Jun 24. doi: 10.1111/aos.14948.
   PubMed         Abstract available
   
   

   
   Am J Clin Nutr

3. WANG H, Yang W, Liu J, Leng J, et al
   Serum concentrations of SFAs and CDKAL1 single-nucleotide polymorphism rs7747752 are related to an increased risk of gestational diabetes mellitus.
   Am J Clin Nutr. 2021 Jun 30. pii: 6311846. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Am J Epidemiol

4. GASTON SA, Atere-Roberts J, Ward J, Slopen NB, et al
   Experiences with Everyday and Major Forms of Racial/Ethnic Discrimination and Type 2 Diabetes Risk among White, Black, and Hispanic/Latina Women: Findings from the Sister Study.
   Am J Epidemiol. 2021 Jul 2. pii: 6313069. doi: 10.1093.
   PubMed         Abstract available
   
   
5. JIANG L, Xu S, Mancuso N, Newcombe PJ, et al
   A Hierarchical Approach Using Marginal Summary Statistics for Multiple Intermediates in a Mendelian Randomization or Transcriptome Analysis.
   Am J Epidemiol. 2021;190:1148-1158.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

6. LEE S, Kim HS, Min BH, Kim BG, et al
   Enhancement of anti-inflammatory and immunomodulatory effects of adipose-derived human mesenchymal stem cells by making uniform spheroid on the new nano-patterned plates.
   Biochem Biophys Res Commun. 2021;552:164-169.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

7. HUANG YD, Luo YR, Lee MC, Yeh CJ, et al
   Factors affecting the growth of children till the age of three years with overweight whose mothers have diabetes mellitus: A population-based cohort study.
   BMC Pediatr. 2021;21:298.
   PubMed         Abstract available
   
   

   
   Circ Cardiovasc Imaging

8. RIPA RS, Zobel EH, von Scholten BJ, Jensen JK, et al
   Effect of Liraglutide on Arterial Inflammation Assessed as [(18)F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
   Circ Cardiovasc Imaging. 2021 Jun 30:CIRCIMAGING120012174.
   PubMed         Abstract available
   
   

   
   Diabet Med

9. SATO K, Babazono T
   Successful Withdrawal of Erythropoiesis-stimulating Agent after Administration of an SGLT2 Inhibitor, Tofogliflozin, in People with Diabetes.
   Diabet Med. 2021 Jul 3:e14632. doi: 10.1111/dme.14632.
   PubMed         Abstract available
   
   
10. CAMPBELL DJT, Campbell DB, Ogundeji Y, Au F, et al
    First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs.
    Diabet Med. 2021 Jun 16:e14622. doi: 10.1111/dme.14622.
    PubMed         Abstract available
    
    
11. NG SM
    User-driven, Open Source Diabetes Technology (special issue) Paediatric DIY APS.
    Diabet Med. 2021 Jun 27:e14630. doi: 10.1111/dme.14630.
    PubMed         Abstract available
    
    

    
    Diabetes

12. 
    Statement of Retraction. Qilong Wang, Zhonglin Xie, Wencheng Zhang, Jun Zhou, Yue Wu, Miao Zhang, Huaiping Zhu, and Ming-Hui Zou. Myeloperoxidase Deletion Prevents High-Fat Diet-Induced Obesity and Insulin Resistance. Diabetes 2014;63:4172-4185. DOI:
    Diabetes. 2021 Jun 28. pii: db21-rt08c. doi: 10.2337.
    PubMed        
    
    

    
    Diabetes Care

13. GIBBINGS NK, Kurdyak PA, Colton PA, Shah BR, et al
    Diabetic Ketoacidosis and Mortality in People With Type 1 Diabetes and Eating Disorders.
    Diabetes Care. 2021 Jun 25. pii: dc21-0517. doi: 10.2337/dc21-0517.
    PubMed         Abstract available
    
    
14. RUTSCH N, Chamberlain CE, Dixon W, Spector L, et al
    Diabetes With Multiple Autoimmune and Inflammatory Conditions Linked to an Activating SKAP2 Mutation.
    Diabetes Care. 2021 Jun 25. pii: dc20-2317. doi: 10.2337/dc20-2317.
    PubMed         Abstract available
    
    
15. ELEFTHERIOU A, Petry CJ, Hughes IA, Ong KK, et al
    The High-Risk Type 1 Diabetes HLA-DR and HLA-DQ Polymorphisms Are Differentially Associated With Growth and IGF-I Levels in Infancy: The Cambridge Baby Growth Study.
    Diabetes Care. 2021 Jun 25. pii: dc20-2820. doi: 10.2337/dc20-2820.
    PubMed         Abstract available
    
    
16. DIMEGLIO LA
    COVID-19 and Type 1 Diabetes: Addressing Concerns and Maintaining Control.
    Diabetes Care. 2021 Jun 26. pii: dci21-0002. doi: 10.2337/dci21-0002.
    PubMed         Abstract available
    
    
17. MEEK CL, Oram RA, McDonald TJ, Feig DS, et al
    Reappearance of C-Peptide During the Third Trimester of Pregnancy in Type 1 Diabetes: Pancreatic Regeneration or Fetal Hyperinsulinism?
    Diabetes Care. 2021 Jun 26. pii: dc21-0028. doi: 10.2337/dc21-0028.
    PubMed         Abstract available
    
    
18. SAM S, Edelstein SL, Arslanian SA, Barengolts E, et al
    Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study.
    Diabetes Care. 2021 Jun 15. pii: dc21-0027. doi: 10.2337/dc21-0027.
    PubMed         Abstract available
    
    
19. PARK J, Zhang P, Wang Y, Zhou X, et al
    High Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries With Diabetes, 1999-2017.
    Diabetes Care. 2021 Jun 28. pii: dc20-2708. doi: 10.2337/dc20-2708.
    PubMed         Abstract available
    
    
20. LEE CH, Seto WK, Lui DT, Fong CH, et al
    Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes.
    Diabetes Care. 2021 Jun 28. pii: dc21-0131. doi: 10.2337/dc21-0131.
    PubMed         Abstract available
    
    
21. PERKINS BA, Lovblom LE, Lewis EJH, Bril V, et al
    Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study.
    Diabetes Care. 2021 Jul 1. pii: dc21-0476. doi: 10.2337/dc21-0476.
    PubMed         Abstract available
    
    
22. CHANG JY, Kim WJ, Kwon JH, Kim BJ, et al
    Prestroke Glucose Control and Functional Outcome in Patients With Acute Large Vessel Occlusive Stroke and Diabetes After Thrombectomy.
    Diabetes Care. 2021 Jul 2. pii: dc21-0271. doi: 10.2337/dc21-0271.
    PubMed         Abstract available
    
    
23. PRAX K, Schmiedel K, Hepp T, Schlager H, et al
    Preventive Care in Type 2 Diabetes: Results of a Randomized, Controlled Trial in Community Pharmacies.
    Diabetes Care. 2021 Jun 30. pii: dc20-2319. doi: 10.2337/dc20-2319.
    PubMed        
    
    
24. REWERS A, Kuppermann N, Stoner MJ, Garro A, et al
    Effects of Fluid Rehydration Strategy on Correction of Acidosis and Electrolyte Abnormalities in Children With Diabetic Ketoacidosis.
    Diabetes Care. 2021 Jun 29. pii: dc20-3113. doi: 10.2337/dc20-3113.
    PubMed         Abstract available
    
    
25. AZAD N, Agrawal L, Bahn G, Emanuele NV, et al
    Eye Outcomes in Veteran Affairs Diabetes Trial (VADT) After 17 Years.
    Diabetes Care. 2021 Jun 29. pii: dc20-2882. doi: 10.2337/dc20-2882.
    PubMed         Abstract available
    
    
26. LI X, Zhou T, Ma H, Liang Z, et al
    Replacement of Sedentary Behavior by Various Daily-Life Physical Activities and Structured Exercises: Genetic Risk and Incident Type 2 Diabetes.
    Diabetes Care. 2021 Jun 28. pii: dc21-0455. doi: 10.2337/dc21-0455.
    PubMed         Abstract available
    
    
27. ROSENSTOCK J, Emral R, Sauque-Reyna L, Mohan V, et al
    Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.
    Diabetes Care. 2021 Jun 28. pii: dc21-0393. doi: 10.2337/dc21-0393.
    PubMed         Abstract available
    
    

    
    Diabetes Obes Metab

28. CHUDASAMA YV, Zaccardi F, Coles B, Gillies CL, et al
    Ethnic, social and multimorbidity disparities in therapeutic inertia: a UK primary care observational study in patients newly diagnosed with type 2 diabetes.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14482.
    PubMed         Abstract available
    
    
29. RETNAKARAN R, Shah BR
    Impact of Pregnancy on the Trajectories of Cardiovascular Risk Factors in Women with and without Gestational Diabetes.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14479.
    PubMed         Abstract available
    
    
30. AMADID H, Ronn PF, Dunbar MB, Knudsen JS, et al
    A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population - a Danish nationwide cohort study.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14478.
    PubMed         Abstract available
    
    
31. BOJER AS, Sorensen MH, Bjerre J, Gaede P, et al
    Metabolic improvement with short-term glucagon like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double-blind placebo-controlled trial.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14480.
    PubMed         Abstract available
    
    
32. QUAST DR, Nauck MA, Schenker N, Menge BA, et al
    Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting GLP-1 receptor agonists in type 2 diabetes.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14477.
    PubMed         Abstract available
    
    
33. BONORA E, Frias JP, Tinahones FJ, Van J, et al
    Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14465.
    PubMed         Abstract available
    
    
34. GONG Q, Zhang P, Wang J, Gregg EW, et al
    Efficacy of lifestyle intervention in adults with impaired glucose tolerance with and without impaired fasting plasma glucose: a post hoc analysis of Da Qing Diabetes Prevention Outcome Study.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14481.
    PubMed         Abstract available
    
    
35. BONNET F, Chen H, Cooper A, Gomes MB, et al
    What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated HbA1c (>/=7.0%) at initiation of second-line therapy? Results from the DISCOVER study.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14476.
    PubMed         Abstract available
    
    
36. CAMERLINGO N, Vettoretti M, Sparacino G, Facchinetti A, et al
    Design of clinical trials to assess diabetes treatments: minimal duration of CGM data to estimate time-in-ranges with a desired precision.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14483.
    PubMed         Abstract available
    
    
37. DAHL K, Baekdal TA
    Response to the letter from Horowitz et al to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14485.
    PubMed        
    
    
38. POWELL RE, Zaccardi F, Beebe C, Chen XM, et al
    Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2021 Jun 27. doi: 10.1111/dom.14455.
    PubMed         Abstract available
    
    
39. HOROWITZ M, Rayner CK, Marathe CS, Wu T, et al
    Response to Dahl et al: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
    Diabetes Obes Metab. 2021 Jun 24. doi: 10.1111/dom.14473.
    PubMed        
    
    
40. FRALICK M, Schneeweiss S, Redelmeier DA, Razak F, et al
    Comparative effectiveness and safety of SGLT2 inhibitors versus metformin in patients with type-2 diabetes: An observational study using data from routine care.
    Diabetes Obes Metab. 2021 Jun 24. doi: 10.1111/dom.14474.
    PubMed         Abstract available
    
    
41. ARNOTT C, Li JW, Cannon CP, de Zeeuw D, et al
    The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
    Diabetes Obes Metab. 2021;23:1652-1659.
    PubMed         Abstract available
    
    
42. BOLLI GB, Cheng A, Charbonnel B, Aroda VR, et al
    Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
    Diabetes Obes Metab. 2021;23:1588-1593.
    PubMed         Abstract available
    
    
43. RASSEN JA, Murk W, Schneeweiss S
    Real-world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias.
    Diabetes Obes Metab. 2021;23:1453-1462.
    PubMed         Abstract available
    
    
44. VERMA S, Fainberg U, Husain M, Rasmussen S, et al
    Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
    Diabetes Obes Metab. 2021;23:1677-1680.
    PubMed         Abstract available
    
    
45. PEREZ FA, Elfers C, Yanovski JA, Shoemaker AH, et al
    MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.
    Diabetes Obes Metab. 2021;23:1532-1541.
    PubMed         Abstract available
    
    
46. SUISSA K, Schneeweiss S, Kim DW, Patorno E, et al
    Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.
    Diabetes Obes Metab. 2021;23:1542-1551.
    PubMed         Abstract available
    
    
47. GHANIM H, Batra M, Green K, Hejna J, et al
    Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors.
    Diabetes Obes Metab. 2021;23:1614-1623.
    PubMed         Abstract available
    
    
48. KLOECKER DE, Davies MJ, Khunti K, Zaccardi F, et al
    Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond.
    Diabetes Obes Metab. 2021;23:1685-1691.
    PubMed         Abstract available
    
    
49. CLARK AL, Yan Z, Chen SX, Shi V, et al
    High fat diet prevents the development of autoimmune diabetes in NOD mice.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14486.
    PubMed         Abstract available
    
    
50. MATSUBAYASHI Y, Yoshida A, Suganami H, Oe M, et al
    Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
    Diabetes Obes Metab. 2021;23:1660-1665.
    PubMed         Abstract available
    
    

    
    Diabetologia

51. KOHLMORGEN C, Gerfer S, Feldmann K, Twarock S, et al
    Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
    Diabetologia. 2021;64:1834-1849.
    PubMed         Abstract available
    
    
52. SCHRAM MT, Assendelft WJJ, van Tilburg TG, Dukers-Muijrers NHTM, et al
    Social networks and type 2 diabetes: a narrative review.
    Diabetologia. 2021 Jun 29. pii: 10.1007/s00125-021-05496.
    PubMed         Abstract available
    
    
53. LIN DS, Lee JK, Chen WJ
    Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors.
    Diabetologia. 2021 Jun 30. pii: 10.1007/s00125-021-05497.
    PubMed         Abstract available
    
    

    
    J Autoimmun

54. MONSTED MO, Falck ND, Pedersen K, Buschard K, et al
    Intestinal permeability in type 1 diabetes: An updated comprehensive overview.
    J Autoimmun. 2021;122:102674.
    PubMed         Abstract available
    
    

    
    J Clin Endocrinol Metab

55. BRIL F, McPhaul MJ, Kalavalapalli S, Lomonaco R, et al
    Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.
    J Clin Endocrinol Metab. 2021 Jun 30. pii: 6311619. doi: 10.1210.
    PubMed         Abstract available
    
    
56. KIVELA J, Sormunen-Harju H, Girchenko PV, Huvinen E, et al
    Longitudinal metabolic profiling of maternal obesity, gestational diabetes and hypertensive pregnancy disorders.
    J Clin Endocrinol Metab. 2021 Jun 29. pii: 6311296. doi: 10.1210.
    PubMed         Abstract available
    
    
57. CHEN H, Zhang J, Wang T, Zhang S, et al
    Type II diabetes mellitus and amyotrophic lateral sclerosis: genetic overlap, causality, and mediation.
    J Clin Endocrinol Metab. 2021 Jun 25. pii: 6309609. doi: 10.1210.
    PubMed         Abstract available
    
    
58. PENG CC, Tu YK, Lee GY, Chang RH, et al
    Effects of Proton Pump Inhibitors on Glycemic Control and Incident Diabetes: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2021 Jun 30. pii: 6298561. doi: 10.1210.
    PubMed         Abstract available
    
    
59. MITCHELL A, Fall T, Melhus H, Lind L, et al
    Type 2 diabetes and Change in Total Hip Bone Area and Bone Mineral Density in Elderly Swedish Men and Women.
    J Clin Endocrinol Metab. 2021 Jul 2. pii: 6313244. doi: 10.1210.
    PubMed         Abstract available
    
    
60. KIM H, Bae JH, Park KS, Sung J, et al
    DNA Methylation Changes Associated with Type 2 Diabetes and Diabetic Kidney Disease in an East Asian Population.
    J Clin Endocrinol Metab. 2021 Jul 2. pii: 6313210. doi: 10.1210.
    PubMed         Abstract available
    
    
61. LIU S, Kuja-Halkola R, Larsson H, Lichtenstein P, et al
    Neurodevelopmental disorders, glycaemic control and diabetic complications in type 1 diabetes: a nationwide cohort study.
    J Clin Endocrinol Metab. 2021 Jun 25. pii: 6309610. doi: 10.1210.
    PubMed         Abstract available
    
    
62. VEZZA T, Victor VM
    The HIF1alpha-PFKFB3 Pathway: a key player in diabetic retinopathy.
    J Clin Endocrinol Metab. 2021 Jun 25. pii: 6309630. doi: 10.1210.
    PubMed        
    
    
63. SCARALE MG, Antonucci A, Cardellini M, Copetti M, et al
    A serum resistin and multi-cytokine inflammatory pathway is linked with and helps predict all-cause death in diabetes.
    J Clin Endocrinol Metab. 2021 Jun 30. pii: 6311725. doi: 10.1210.
    PubMed         Abstract available
    
    

    
    J Diabetes Complications

64. DE ARAUJO LIRA AL, de Fatima Mello Santana M, de Souza Pinto R, Minanni CA, et al
    Serum albumin modified by carbamoylation impairs macrophage cholesterol efflux in diabetic kidney disease.
    J Diabetes Complications. 2021 May 28:107969.
    PubMed         Abstract available
    
    
65. SURYANI M, Samekto W, Heri-Nugroho, Susanto H, et al
    Effect of foot-ankle flexibility and resistance exercise in the secondary prevention of plantar foot diabetic ulcer.
    J Diabetes Complications. 2021 May 28:107968.
    PubMed         Abstract available
    
    
66. PULIDO-PEREZ P, Torres-Rasgado E, Perez-Fuentes R, Rosales-Encina JL, et al
    Disordered glycemic control in women with type 2 diabetes is associated with increased TNF receptor-2 levels.
    J Diabetes Complications. 2021 Jun 19:107974.
    PubMed         Abstract available
    
    
67. ALHINAI A, Patel K, Fonseca VA, Sebastiani G, et al
    Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.
    J Diabetes Complications. 2021 Jun 19:107978.
    PubMed         Abstract available
    
    
68. BOYE KS, Lage MJ, Thieu V, Shinde S, et al
    Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data.
    J Diabetes Complications. 2021 Jun 19:107975.
    PubMed         Abstract available
    
    
69. ABELL TL, Garcia LM, Wiener GJ, Wo JM, et al
    Effect of Oral CNSA-001 (sepiapterin, PTC923) on gastric accommodation in women with diabetic gastroparesis: A randomized, placebo-controlled, Phase 2 trial.
    J Diabetes Complications. 2021 Jun 17:107961.
    PubMed         Abstract available
    
    
70. DAI D, Shen Y, Lu J, Wang Y, et al
    Association between visit-to-visit variability of glycated albumin and diabetic retinopathy among patients with type 2 diabetes - A prospective cohort study.
    J Diabetes Complications. 2021 May 29:107971.
    PubMed         Abstract available
    
    

    
    JAMA

71. WANG L, Li X, Wang Z, Bancks MP, et al
    Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes Among US Adults, 1999-2018.
    JAMA. 2021 Jun 25. pii: 2781620. doi: 10.1001/jama.2021.9883.
    PubMed         Abstract available
    
    

    
    Kidney Int

72. WHEELER DC, Toto RD, Stefansson BV, Jongs N, et al
    A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
    Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00396.
    PubMed         Abstract available
    
    

    
    Lancet

73. TAN TM, Khoo B
    Tirzepatide and the new era of twincretins for diabetes.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01390.
    PubMed        
    
    
74. ROSENSTOCK J, Wysham C, Frias JP, Kaneko S, et al
    Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01324.
    PubMed         Abstract available
    
    

    
    Med Care

75. NEILSON LM, Munshi KD, Peasah SK, Huang Y, et al
    Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014-2019.
    Med Care. 2021 Jun 29. pii: 00005650-900000000-98133.
    PubMed         Abstract available
    
    

    
    Med J Aust

76. ZAJAC JD, Andrikopoulos S
    Diabetes care for hospital patients in Australia needs repair.
    Med J Aust. 2021 Jun 28. doi: 10.5694/mja2.51160.
    PubMed        
    
    

    
    N Engl J Med

77. GERSTEIN HC, Sattar N, Rosenstock J, Ramasundarahettige C, et al
    Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
    N Engl J Med. 2021 Jun 28. doi: 10.1056/NEJMoa2108269.
    PubMed         Abstract available
    
    
78. FRIAS JP, Davies MJ, Rosenstock J, Perez Manghi FC, et al
    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    N Engl J Med. 2021 Jun 25. doi: 10.1056/NEJMoa2107519.
    PubMed         Abstract available
    
    
79. TUTTLE KR
    Breaking New Ground with Incretin Therapy in Diabetes.
    N Engl J Med. 2021 Jun 25. doi: 10.1056/NEJMe2109957.
    PubMed        
    
    

    
    Ophthalmology

80. KANCLERZ P, Hecht I, Tuuminen R
    Re: Lois et al.: Evaluation of a new model of care for people with complications of diabetic retinopathy: The EMERALD Study (Ophthalmology. 2021;128:561-573).
    Ophthalmology. 2021 Jun 24. pii: S0161-6420(21)00371.
    PubMed        
    
    

    
    Pediatr Diabetes

81. GIRAUDO F, Lalanne I, Valdes I, Gajardo A, et al
    Risky sexual behaviors in adolescents and young adult women with type 1 diabetes: An overlooked problem.
    Pediatr Diabetes. 2021 Jun 30. doi: 10.1111/pedi.13245.
    PubMed         Abstract available
    
    
82. PAPADAKIS JL, Shapiro JB, Evans M, Feldman MA, et al
    Psychometric Properties of the Diabetes Skills Checklist for Adolescents with Type 1 Diabetes and their Parents.
    Pediatr Diabetes. 2021 Jun 26. doi: 10.1111/pedi.13241.
    PubMed         Abstract available
    
    
83. YAGHOUBPOUR K, Tasdighi E, Abdi H, Barzin M, et al
    Association of obesity phenotypes in adolescents and incidence of early adulthood Type 2 Diabetes Mellitus: Tehran Lipid and Glucose Study.
    Pediatr Diabetes. 2021 Jun 26. doi: 10.1111/pedi.13243.
    PubMed         Abstract available
    
    
84. VERSLOOT J, Ali A, Minotti SC, Ma J, et al
    All Together: Integrated care for youth with Type 1 Diabetes.
    Pediatr Diabetes. 2021 Jun 26. doi: 10.1111/pedi.13242.
    PubMed         Abstract available
    
    
85. KUMAR S, Kumar R, Rohilla L, Jacob N, et al
    A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study.
    Pediatr Diabetes. 2021 Jun 26. doi: 10.1111/pedi.13244.
    PubMed         Abstract available
    
    

    
    Pediatrics

86. STROM MS, Tollanes MC, Wilcox AJ, Lie RT, et al
    Maternal Chronic Conditions and Risk of Cerebral Palsy in Offspring: A National Cohort Study.
    Pediatrics. 2021;147.
    PubMed         Abstract available
    
    
87. OGLE SB, Dewberry LC, Jenkins TM, Inge TH, et al
    Outcomes of Bariatric Surgery in Older Versus Younger Adolescents.
    Pediatrics. 2021;147.
    PubMed         Abstract available
    
    

    
    PLoS Med

88. WEI X, Zhang Z, Chong MKC, Hicks JP, et al
    Evaluation of a package of risk-based pharmaceutical and lifestyle interventions in patients with hypertension and/or diabetes in rural China: A pragmatic cluster randomised controlled trial.
    PLoS Med. 2021;18:e1003694.
    PubMed         Abstract available
    
    
89. EASTWOOD SV, Mathur R, Sattar N, Smeeth L, et al
    Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006-2019: A cohort study.
    PLoS Med. 2021;18:e1003672.
    PubMed         Abstract available
    
    

    
    PLoS One

90. JUNKER K, Buckley CM, Millar SR, Flynn S, et al
    The prevalence and correlates of pre-diabetes in middle- to older-aged Irish adults using three diagnostic methods.
    PLoS One. 2021;16:e0253537.
    PubMed         Abstract available
    
    
91. FAGBAMIGBE AF, Norrman E, Bergh C, Wennerholm UB, et al
    Comparison of the performances of survival analysis regression models for analysis of conception modes and risk of type-1 diabetes among 1985-2015 Swedish birth cohort.
    PLoS One. 2021;16:e0253389.
    PubMed         Abstract available
    
    
92. MAN B, Schwartz A, Pugach O, Xia Y, et al
    A clinical diabetes risk prediction model for prediabetic women with prior gestational diabetes.
    PLoS One. 2021;16:e0252501.
    PubMed         Abstract available
    
    
93. CARPES LS, Nicoletto BB, Canani LH, Rheinhemer J, et al
    Could serum zonulin be an intestinal permeability marker in diabetes kidney disease?
    PLoS One. 2021;16:e0253501.
    PubMed         Abstract available
    
    
94. LAOWAHUTANON T, Nakamura H, Tachimori H, Nomura S, et al
    Hospital admission for type 2 diabetes mellitus under the Universal Coverage Scheme in Thailand: A time- and geographical-trend analysis, 2009-2016.
    PLoS One. 2021;16:e0253434.
    PubMed         Abstract available
    
    
95. BRATT G, Brannstrom J, Missalidis C, Nystrom T, et al
    Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors.
    PLoS One. 2021;16:e0254079.
    PubMed         Abstract available
    
    

    
    Transplantation

96. BRODOSI L, Petta S, Petroni ML, Marchesini G, et al
    Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients.
    Transplantation. 2021 Jun 23. pii: 00007890-900000000-95221.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: